Reducing joint pain within three hours: Lanconone ingredient bolstered by clinical evidence

15 Jan 2020 --- Enovate Biolife’s botanical ingredient Lanconone can provide joint pain relief within three hours of the first dose. Available in North American and Asian markets, Lanconone serves as a natural alternative to ibuprofen for daily aches and pains, in addition to being a recovery formula for aging or stressed joints. The new human trial revealed the ingredient’s ability to provide improvement in joint pain relief, stiffness and mobility without any side effects, allowing the company to address growing consumer demands in the joint health and mobility space. 

“Lanconone has gained the proven claim of being the ‘world’s first clinically proven botanical ingredient for rapid pain relief comparable to ibuprofen.’ Therefore, applications are vast across the sports and fitness sectors, and for high-intensity training and athletes,” Amol Pathak, Director Business and Strategy at Enovate Biolife, tells NutritionInsight.

The new study revealed a 46 percent improvement in joint pain compared to only 19 percent improvement with subjects taking a placebo, as well as a 44 percent improvement in joint stiffness compared to only 15 percent improvement with the placebo-taking subjects.

Lanconone is primarily aimed at helping active adults curb daily pain associated with physical exertion and performance, as well as joint mobility and flexibility. For its elderly users, the ingredient can slow down degenerative joint changes in addition to joint pain relief. 

Joint health is becoming increasingly important to younger consumers as well as the elderly.Study parameters
Published in the Journal of Pain Research, the research team from India and the US conducted an 8-week randomized, double-blind, placebo-controlled, parallel clinical trial with male and female participants aged between 40 and 65 years old. 

These patients demonstrated significant improvement in joint pain, stiffness and mobility. Concerning overall joint function, the study indicated a 41 percent improvement.

Market expansion
While Lanconone has been commercially available in the US, Canada and Malaysia for the last eight years, Enovate Biolife is currently eyeing expansion to the European market once the European Food Safety Authority (EFSA) hurdle is crossed, Pathak notes.

Ingredient details
Lanconone arrives in a free-flowing brown powder containing extracts derived from Commiphora mukul, Boswellia serrata, Oroxylum indicum and Pluchea lanceolata, all of which are botanicals native to Central and Eastern Asia. It also includes trending ingredients in the naturality space, such as ashwagandha, china root and ginger. Lanconone is halal, kosher, US Dietary Supplement Health and Education Act (US DSHEA)-compliant and Health Canada-approved. It is also free from GMO, gluten and allergens. 

The ingredient works by itself and together with other joint health ingredients, such as glucosamine, chondroitin, for superior joint comfort. A key advantage is that Lanconone did not indicate any serious side effects in the study, which non-steroidal anti-inflammatory drugs (NSAIDs) are prone to exhibit. Although NSAIDs are touted for reducing osteoporosis symptoms, the US Food and Drug Administration (FDA) warns about the side effects NSAID consumption may present, such as gastrointestinal bleeding, heart attack and stroke.

By Anni Schleicher

To contact our editorial team please email us at editorial@cnsmedia.com